BOTHELL, WA and VANCOUVER, Sept. 3 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. announced today that the company will webcast presentations at the following investor conferences:
Access to a live webcast of each of the presentations will be available on the Events Presentation section of the Investor Relations page on the company Web site at www.oncogenex.com. A replay of each webcast will be available for 30 days following the event.
About OncoGenex
OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address unmet needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the lead candidate that has completed five Phase 2 clinical studies in prostate, lung and breast cancers, is designed to inhibit the production of a specific protein associated with treatment resistance; OGX-427 is in Phase 1 clinical development; SN2310 has completed the Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development. More information about OncoGenex is available at www.oncogenex.com.
SOURCE OncoGenex Pharmaceuticals, Inc.
CONTACT: OncoGenex Contact: Scott Cormack, President CEO, (604)
630-5400, scormack@oncogenex.com; Media and Investor Contact: Jason Spark,
Porter Novelli Life Sciences, (619) 849-6005, jspark@pnlifesciences.com
